We also demonstrated that the expression of G0S2 was higher in post-operative recurrence diagnosed as WHO grade IV secondary GBM compared with initial glioma diagnosed as WHO grade II diffuse astrocytoma in the same patient. This evidence concerns the gene G0S2 and central nervous system cancer.